Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

Nenhuma Miniatura disponível
Citações na Scopus
24
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Dimensions
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER INC
Autores
RAZAVI-SHEARER, Devin M.
GAMKRELIDZE, Ivane
PAN, Calvin Q.
JIA, Jidong
BERG, Thomas
GRAY, Richard T.
LIM, Young-Suk
CHEN, Chien-Jen
OCAMA, Ponsiano
DESALEGN, Hailemichael
Citação
LANCET GASTROENTEROLOGY & HEPATOLOGY, v.8, n.10, p.879-907, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background The 2016 World Health Assembly endorsed the elimination of hepatitis B virus (HBV) infection as a public health threat by 2030; existing therapies and prophylaxis measures make such elimination feasible, even in the absence of a virological cure. We aimed to estimate the national, regional, and global prevalence of HBV in the general population and among children aged 5 years and younger, as well as the rates of diagnosis, treatment, prophylaxis, and the future burden globally. Methods In this modelling study, we used a Delphi process with data from literature reviews and interviews with country experts to quantify the prevalence, diagnosis, treatment, and prevention measures for HBV infection. The PRoGReSs Model, a dyn amic Markov model, was used to estimate the country, regional, and global prevalence of HBV infection in 2022, and the effects of treatment and prevention on disease burden. The future incidence of morbidity and mortality in the absence of additional interventions was also estimated at the global level. Findings We developed models for 170 countries which resulted in an estimated global prevalence of HBV infection in 2022 of 3.2% (95% uncertainty interval 2.7-4.0), corresponding to 257.5 million (216.6-316.4) individuals positive for HBsAg. Of these individuals, 36.0 million were diagnosed, and only 6.8 million of the estimated 83.3 million eligible for treatment were on treatment. The prevalence among children aged 5 years or younger was estimated to be 0.7% (0.6-1.0), corresponding to 5.6 million (4.5-7.8) children with HBV infection. Based on the most recent data, 85% of infants received three-dose HBV vaccination before 1 year of age, 46% had received a timely birth dose of vaccine, and 14% received hepatitis B immunoglobulin along with the full vaccination regimen. 3% of mothers with a high HBV viral load received antiviral treatment to reduce mother-to-child transmission. Interpretation As 2030 approaches, the elimination targets remain out of reach for many countries under the current frameworks. Although prevention measures have had the most success, there is a need to increase these efforts and to increase diagnosis and treatment to work towards the elimination goals.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/58891
Referências
  1. ADACHI H, 1992, HEPATOLOGY, V16, P1334, DOI 10.1002/hep.1840160605
  2. Ahn SH, 2005, J HEPATOL, V42, P188, DOI 10.1016/j.jhep.2004.10.026
  3. Alberts CJ, 2022, LANCET GASTROENTEROL, V7, P724, DOI 10.1016/S2468-1253(22)00050-4
  4. Ando R, 2020, HEPATOL RES, V50, P892, DOI 10.1111/hepr.13504
  5. [Anonymous], 2013, Global policy report on the prevention and control of viral hepatitis
  6. Chan TT, 2020, AM J GASTROENTEROL, V115, P867, DOI 10.14309/ajg.0000000000000588
  7. Chen CJ, 2011, J GASTROEN HEPATOL, V26, P628, DOI 10.1111/j.1440-1746.2011.06695.x
  8. Chinese Society of Hepatology Chinese Medical Association, 2022, Zhonghua Gan Zang Bing Za Zhi, V30, P1309, DOI 10.3760/cma.j.cn501113-20221204-00607
  9. Chu CM, 2007, HEPATOLOGY, V45, P1187, DOI 10.1002/hep.21612
  10. Coffin CS, 2018, CAN LIVER J, V1, P156, DOI 10.3138/canlivj.2018-0008
  11. Cuenca-Gómez JA, 2016, REV CLIN ESP, V216, P248, DOI 10.1016/j.rce.2016.02.005
  12. de Martel C, 2020, LANCET GLOB HEALTH, V8, pE180, DOI 10.1016/S2214-109X(19)30488-7
  13. Duberg AS, 2022, HEPATOL COMMUN, V6, P2418, DOI 10.1002/hep4.1974
  14. Duffell E, 2021, J VIRAL HEPATITIS, V28, P1177, DOI 10.1111/jvh.13545
  15. European Assoc Study Liver, 2017, J HEPATOL, V67, P370, DOI 10.1016/j.jhep.2017.03.021
  16. Gane EJ, 2020, Gastroenterol Hepatol, V11, P57
  17. Gigi E, 2007, J GASTROINTEST LIVER, V16, P19
  18. Ho E, 2020, ANN GLOB HEALTH, V86, DOI 10.5334/aogh.2848
  19. Hope VD, 2014, EPIDEMIOL INFECT, V142, P270, DOI 10.1017/S0950268813000940
  20. Ismail Z, 2022, INT J HEALTH PLAN M, V37, P547, DOI 10.1002/hpm.3317
  21. Kao JH, 2010, ADV CANCER RES, V108, P21, DOI 10.1016/S0065.230X(10)08003.6
  22. Khetsuriani N, 2022, MMWR-MORBID MORTAL W, V71, P958, DOI 10.15585/mmwr.mm7130a2
  23. Koc ÖM, 2019, J MED VIROL, V91, P1479, DOI 10.1002/jmv.25457
  24. MALCOLM DG, 1959, OPER RES, V7, P646, DOI 10.1287/opre.7.5.646
  25. Maucort-Boulch D, 2018, INT J CANCER, V142, P2471, DOI 10.1002/ijc.31280
  26. Nayagam S, 2023, LANCET GASTROENTEROL, V8, DOI 10.1016/S2468-1253(23)00074-2
  27. Nayagam S, 2016, LANCET INFECT DIS, V16, P1399, DOI 10.1016/S1473-3099(16)30204-3
  28. Negro F, 2023, SWISS MED WKLY, V153, DOI 10.57187/smw.2023.40086
  29. Ng E, 2022, HEALTH REP, V33, P30, DOI 10.25318/82-003-x202200600003-eng
  30. Nguyen MH, 2019, J INFECT DIS, V219, P10, DOI 10.1093/infdis/jiy391
  31. Nichols E, 2022, LANCET PUBLIC HEALTH, V7, pE105, DOI 10.1016/S2468-2667(21)00249-8
  32. Ott JJ, 2012, VACCINE, V30, P2212, DOI 10.1016/j.vaccine.2011.12.116
  33. PAHO, 2016, Hepatitis B and C in the spotlight. A public health response in the Americas
  34. Pan CQ, 2022, HEPATOLOGY, V76, pS1
  35. Picchio CA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-96350-3
  36. Razavi-Shearer D, 2023, LANCET REG HEALTH-AM, V22, DOI 10.1016/j.lana.2023.100516
  37. Razavi-Shearer D, 2018, LANCET GASTROENTEROL, V3, P383, DOI 10.1016/S2468-1253(18)30056-6
  38. Reikvam DG, 2023, Norsk forening for infeksjonsmedisin, den norske legeforening
  39. Schweitzer A, 2015, LANCET, V386, P1546, DOI 10.1016/S0140-6736(15)61412-X
  40. Sharma S, 2015, J HEPATOL, V63, P515, DOI 10.1016/j.jhep.2015.04.026
  41. Thompson P, 2023, J INFECT DIS, V228, P368, DOI 10.1093/infdis/jiad026
  42. Tout I, 2020, J HEPATOL, V73, P409, DOI 10.1016/j.jhep.2020.04.013
  43. Wang GQ, 2021, J CLIN TRANSL HEPATO, V9, P769, DOI 10.14218/JCTH.2021.00209
  44. WHO, 2021, INT GUID COUNTR VAL
  45. WHO, 2020, Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy: web annex A: systematic review of the efficacy and safety of antiviral therapy during pregnancy
  46. WHO UNICEF, 2022, WHO/UNICEF estimates of national immunization coverage
  47. World Health Organization, 2022, Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030
  48. World Health Organization, 2021, GLOB PROGR REP HIV V
  49. World Hepatitis Alliance, 2023, LANCET GASTROENTEROL, V8, P115, DOI 10.1016/S2468-1253(22)00422-8
  50. Yip TCF, 2018, CLIN GASTROENTEROL H, V16, P765, DOI 10.1016/j.cgh.2017.12.009
  51. Zacharakis GH, 2005, J MED VIROL, V77, P173, DOI 10.1002/jmv.20434

Coleções
Artigos e Materiais de Revistas Científicas - FM/MIP